MYGN:NSD-Myriad Genetics Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 26.23

Change

+0.14 (+0.54)%

Market Cap

USD 2.51B

Volume

0.62M

Analyst Target

USD 15.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+11.27 (+2.26%)

USD 41.71B
ICLR ICON PLC

+2.21 (+0.78%)

USD 25.10B
ILMN Illumina Inc

+6.12 (+4.85%)

USD 20.90B
NTRA Natera Inc

-1.14 (-0.91%)

USD 15.80B
EXAS EXACT Sciences Corporation

+0.17 (+0.25%)

USD 13.09B
MEDP Medpace Holdings Inc

+5.68 (+1.77%)

USD 11.34B
RDNT RadNet Inc

-1.81 (-2.55%)

USD 5.13B
SHC Sotera Health Co

N/A

USD 4.69B
NEOG Neogen Corporation

+0.21 (+1.28%)

USD 3.78B
GH Guardant Health Inc

+0.43 (+1.93%)

USD 3.09B

ETFs Containing MYGN

HEP:CA 6.18 % 0.83 %

N/A

N/A
MXF:CA 4.70 % 0.74 %

N/A

N/A
GNOG:LSE Global X Genomics & Biote.. 4.25 % 0.00 %

N/A

USD 6.06M
GN0M:XETRA Global X Genomics & Biote.. 4.22 % 0.00 %

-0.01 (-0.23%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.22 % 0.00 %

-0.02 (-0.23%)

USD 6.06M
GNOM Global X Genomics & Biote.. 4.16 % 0.00 %

+0.16 (+-0.23%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.04% 86% B+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.04% 86% B+ 86% B+
Trailing 12 Months  
Capital Gain 56.22% 84% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.22% 84% B 86% B+
Trailing 5 Years  
Capital Gain -7.87% 63% D 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.87% 63% D 40% F
Average Annual (5 Year Horizon)  
Capital Gain 16.10% 70% C- 74% C
Dividend Return 16.10% 70% C- 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 61.92% 48% F 28% F
Risk Adjusted Return 26.00% 78% C+ 59% D-
Market Capitalization 2.51B 72% C 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector